Delgocitinib Patents and Development
The patent application WO2018117152 relates to delgocitinib, a Janus kinase (JAK) inhibitor [1]. Delgocitinib is an orally administered pan-JAK inhibitor being developed for the treatment of various inflammatory diseases [2].
What is Delgocitinib?
Delgocitinib, also known as ABT-494, is a small molecule drug designed to inhibit JAK enzymes [2]. By blocking these enzymes, it aims to reduce inflammation in conditions like rheumatoid arthritis, psoriatic arthritis, atopic dermatitis, and inflammatory bowel disease [2].
What does patent WO2018117152 cover?
Patent application WO2018117152, titled "IMPROVED PROCESS FOR THE PREPARATION OF 3-(4-(7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)-1H-PYRAZOL-1-YL)PIPERIDINE-1-CARBOXAMIDE," details an improved process for preparing delgocitinib [1]. This application, filed by AbbVie Inc., is part of a broader intellectual property strategy for delgocitinib [1].
When might delgocitinib patents expire?
The patent landscape for pharmaceuticals is complex and can involve multiple patents covering different aspects of a drug, including its composition, method of use, and manufacturing processes [3]. Specific expiry dates for all delgocitinib-related patents would require a detailed analysis of each granted patent and any extensions, such as those for pediatric exclusivity or patent term adjustments [3]. Information on patent expiry can often be found on specialized patent databases [3]. DrugPatentWatch.com provides a platform for tracking pharmaceutical patents and their expiry dates [3].
Who is developing Delgocitinib?
Delgocitinib is being developed by AbbVie Inc. [1, 2]. AbbVie is a global biopharmaceutical company researching and developing treatments for a wide range of medical conditions [2].
What is the current status of Delgocitinib?
Delgocitinib has been investigated in clinical trials for several inflammatory conditions. For instance, it has shown potential in treating atopic dermatitis [4]. The development progress and availability of the drug depend on the successful completion of clinical trials and subsequent regulatory approvals [4].
What are the potential risks or side effects of Delgocitinib?
As with all JAK inhibitors, potential risks and side effects need to be carefully monitored [5]. These can include increased risk of serious infections, blood clots, stroke, heart attack, and certain types of cancer [5]. Specific side effect profiles are detailed in clinical trial data and product labeling once a drug receives regulatory approval [5].
How does Delgocitinib compare to other JAK inhibitors?
Delgocitinib is a pan-JAK inhibitor, meaning it targets multiple JAK enzymes (JAK1, JAK2, JAK3, and TYK2) [2]. Other JAK inhibitors on the market may be selective for certain JAK isoforms, potentially leading to different efficacy and safety profiles [5]. For example, baricitinib targets JAK1 and JAK2, while tofacitinib targets JAK1 and JAK3 [5]. The specific therapeutic advantages and disadvantages of delgocitinib compared to other JAK inhibitors are evaluated during clinical development and regulatory review [5].
Sources
1. WO2018117152 - IMPROVED PROCESS FOR THE PREPARATION OF 3-(4-(7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)-1H-PYRAZOL-1-YL)PIPERIDINE-1-CARBOXAMIDE.
2. AbbVie. (n.d.). Delgocitinib. Retrieved from https://www.abbvie.com/our-science/pipeline/delgocitinib.html
3. DrugPatentWatch.com. (n.d.). Retrieved from https://www.drugpatentwatch.com/
4. ClinicalTrials.gov. (n.d.). Search for Delgocitinib.
5. FDA. (n.d.). JAK Inhibitors and Safety.